Synaffix is a biotechnology company enabling highly-competitive targeted cancer therapeutics using its site-specific antibody-drug conjugate (ADC) technology platform. The platform consistently delivers more effective and better tolerated ADCs compared to all 3 major clinical-stage technologies.
The business model of Synaffix is technology out-licensing where granted patents provide end-to-end protection of the technology and resulting product candidates thru at least 2035.
We anticipate the first-in-human studies evaluating Synaffix ADC technology to be initiated by our partners in 2018.
Area of work
Oncology, Antibody Drug Conjugates